Open-Label, Non Randomized Phase 2 Study With Safety Run-In
Status:
Completed
Trial end date:
2018-09-11
Target enrollment:
Participant gender:
Summary
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the
Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib
(PQR309) administered orally, as once daily capsules continuously and on intermittent
schedule in patients with relapsed or refractory lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
PIQUR Therapeutics AG
Collaborators:
Centre Hospitalier Lyon Sud Churchill Hospital Clinical Center Kragujevac Clinical Center Nis, Nis Clinical Center of Vojvodina Clinical Hospital Centre Zagreb Groupe Hospitalier Pitie-Salpetriere Institut Curie Institute for Oncology and Radiology Serbia Institute for Oncology and Radiology Serbia, Belgrade Oncology Institute of Southern Switzerland Roswell Park Cancer Institute Royal Marsden NHS Foundation Trust Saint-Louis Hospital, Paris, France University Clinical Center Republic of Srpska University Clinical Center, Sarajevo University Clinical Centre of Republic of Srpska University College London Hospitals University Hospital Munich University Hospital, Basel, Switzerland University of Haifa Weill Medical College of Cornell University